Taj Khan, DO
Ophthalmology · Rahway, NJNPI 1851480917
Payments from drug & device makers
Across 199 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$776
- Alcon$536
- Sight Sciences, Inc.$408
- Bausch & Lomb Americas Inc.$364
- Glaukos Corporation$337
- Kala Pharmaceuticals, Inc.$316
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,289100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $776 |
| Alcon | 25 | $536 |
| Sight Sciences, Inc. | 5 | $408 |
| Bausch & Lomb Americas Inc. | 18 | $364 |
| Glaukos Corporation | 2 | $337 |
| Kala Pharmaceuticals, Inc. | 20 | $316 |
| Biotissue Holdings Inc. | 3 | $216 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $207 |
| Novartis | 15 | $197 |
| Sun Pharmaceutical Industries Inc. | 12 | $168 |
| Tarsus Pharmaceuticals, Inc. | 10 | $168 |
| Oyster Point Pharma, Inc. | 8 | $136 |
| NEW World Medical,inc. | 2 | $93 |
| Ocular Therapeutix, Inc. | 1 | $77 |
| Mallinckrodt Hospital Products Inc. | 3 | $62 |
| Eyevance Pharmaceuticals LLC | 4 | $60 |
| Merz North America, Inc. | 2 | $60 |
| Amgen | 2 | $29 |
| Travere Therapeutics, Inc. | 1 | $22 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Shire North American Group Inc | 1 | $14 |
| Dompe US, Inc. | 1 | $14 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$370
- SION SURGICAL INSTRUMENT$370
- enVista MX60 IOL$255
- iDoseTR$178
- iStent$178
- iDose$159
- Hydrus Microstent$150
- DURYSTA$123
How this compares
$4,289 in reported general payments places this provider in the 75th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 34 | $29,933 |
| RestasisCyclosporine | 34 | $28,491 |
| LumiganBimatoprost | 24 | $13,395 |
| MieboPerfluorohexyloctane/Pf | 13 | $9,392 |
| VyzultaLatanoprostene Bunod | 13 | $8,284 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $6,562 |
| Cyclosporine | 14 | $5,996 |
| TobradexTobramycin/Dexamethasone | 18 | $4,812 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $4,542 |
| Prednisolone Acetate | 112 | $3,327 |
| Lotemax SmLoteprednol Etabonate | 13 | $3,187 |
| Ketorolac Tromethamine | 84 | $2,460 |
| Brinzolamide | 15 | $2,446 |
| BesivanceBesifloxacin Hcl | 11 | $2,392 |
| Ofloxacin | 210 | $2,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $364 | $47,60860 claims |
| AbbVieRestasis, Lumigan | $776 | $41,88658 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $12 | $6,56220 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Besivance | $207 | $5,57924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Rahway
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.